What category does this event fall under?

Business — classified as private placement.

What is the sentiment of coverage?

Aggregate sentiment score: 10 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

VivoSim Labs entered securities purchase agreement · VivoSim Labs agreed to amend warrants · VivoSim Labs filed registration statement United States — United States Securities and Exchange Commission

Is this event still developing?

This is an active story, last updated Jul 16, 2026. Coverage continues to evolve.

Business private placement

VivoSim Labs $4M Private Placement

Q: When did this event occur?

First reported Jul 16, 2026; last updated Jul 16, 2026.

Q: Who was involved?

Top entities: VivoSim Labs, Alliance Global Partners, United States — United States Securities and Exchange Commission, United States — Food and Drug Administration.

Q: What is the market impact?

General. The private placement provides VivoSim Labs with $4 million in working capital, supporting its operations in the NAM-based preclinical testing market.

Analysis based on 6 articles · First reported Jul 16, 2026 · Last updated Jul 16, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The private placement provides VivoSim Labs with $4 million in working capital, supporting its operations in the NAM-based preclinical testing market. The dilutive offering may pressure the stock price in the short term, but the capital infusion could fund growth initiatives.

Biotechnology Pharmaceutical

Event Summary

VivoSim Labs, Inc. (Nasdaq: VIVS) announced a securities purchase agreement with a single healthcare-focused institutional investor for the sale of 4,705,883 shares of common stock and warrants at $0.85 per share, raising approximately $4.0 million in gross proceeds. The company also agreed to amend existing May 2024 warrants with a reduced exercise price of $0.85 per share, subject to stockholder approval. The offering is expected to close on July 17, 2026, with net proceeds used for working capital and general corporate purposes. Alliance Global Partners acted as sole placement agent. The securities are offered under an exemption from registration, and VivoSim will file a resale registration statement with the SEC.

Key Actions

80 VivoSim Labs entered securities purchase agreement

60 VivoSim Labs agreed to amend warrants

30 VivoSim Labs filed registration statement United States — United States Securities and Exchange Commission

Entities Involved

priv

VivoSim Labs

VivoSim Labs is the issuer of the private placement, raising $4 million for working capital. The offering includes shares and warrants at $0.85 per share, with existing warrants amended to the same price.

Importance 100.0 Sentiment 10.0

priv

Alliance Global Partners

Alliance Global Partners acted as the sole placement agent for the offering, facilitating the transaction.

Importance 30.0 Sentiment 0.0

govactor

United States — United States Securities and Exchange Commission

VivoSim will file a registration statement with the SEC covering the resale of shares and warrants sold in the offering.

Importance 20.0 Sentiment 0.0

govactor

United States — Food and Drug Administration

The FDA's roadmap to refine animal testing requirements is mentioned as a potential catalyst for VivoSim's NAM models, but no direct action in this event.

Importance 10.0 Sentiment 0.0

Relationships

Alliance Global Partners related ↔ United States — United States Securities and Exchange Commission

United States — United States Securities and Exchange Commission related ↔ United States — Food and Drug Administration

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard